The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

M&A Update

Following our last update, there have been a considerable number of bio/pharma M&A developments, so to bring you up to speed

… from most to least definite:

Millipore is buying Guava Technologies (flow cytometry) for $22.6 million.

Lundbeck is acquiring Ovation Pharmaceuticals.  Interesting side-note: Ovation appears to have marketing rights for ATryn (you know, the goat milk drug).  It also has a CNS pipeline.

Also, a baby IPO (har): BMS is offering about 12.5% of Mead Johnson this week.

We got quite a bit more detail on Roche’s bid for Genentech, which even at the initial $89 per share was $23 per share less than Genetech was looking for.  As WSJ’s health blog notes, yesterday’s closing price suggests there’s still significant doubt about the offer’s prospects. (By the way, if you want to start getting used to the SEC’s new XBRL reports, Genentech’s latest quarterly numbers are available in the SEC’s new viewer.)

GSK may buy into the generics business in India.

P&G thinks the pharma business is a drag.

Sanofi’s new CEO will hold his first press confrerence tomorrow, and analyst speculation is that acquisitions will be on the table.

Bookmark and Share

About these ads

One response to “M&A Update

  1. Pingback: M&A Update 2 « The Cross-Border Biotech Blog

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 129 other followers